BIO appreciates the opportunity to comment on the intellectual property rights issues affecting U.S. biotechnology companies abroad. We hope our contribution will assist the efforts in preserving strong intellectual property protections for United States’ companies internationally.
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
BIO appreciates the opportunity to comment on the intellectual property rights issues affecting U.S. biotechnology companies abroad. We hope our contribution will assist the efforts in preserving strong intellectual property protections for United States’ companies internationally.